Reduced IL-22 levels in PCOS individuals, while IL-22 administration improves insulin resistance, menstrual cycle disorders, and ovarian morphological abnormalities, making it a potential treatment for PCOS with hyperandrogenism phenotypes (Qi et al., 2020). This evidence concerns the gene IL22 and Insulin resistance.